- Home
- ZEO vs PMCB Comparison
ZEO vs PMCB Comparison
Compare ZEO & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- PMCB
- Stock Information
- Founded
- ZEO 2005
- PMCB 1996
- Country
- ZEO United States
- PMCB United States
- Employees
- ZEO N/A
- PMCB 2
- Industry
- ZEO
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZEO
- PMCB Health Care
- Exchange
- ZEO NYSE
- PMCB Nasdaq
- Market Cap
- ZEO 25.7M
- PMCB 11.4M
- IPO Year
- ZEO N/A
- PMCB N/A
- Fundamental
- Price
- ZEO $2.04
- PMCB $1.64
- Analyst Decision
- ZEO
- PMCB
- Analyst Count
- ZEO 0
- PMCB 0
- Target Price
- ZEO N/A
- PMCB N/A
- AVG Volume (30 Days)
- ZEO 2.7M
- PMCB 14.0K
- Earning Date
- ZEO 12-31-2024
- PMCB 12-24-2024
- Dividend Yield
- ZEO N/A
- PMCB N/A
- EPS Growth
- ZEO N/A
- PMCB N/A
- EPS
- ZEO 0.67
- PMCB 0.74
- Revenue
- ZEO $95,455,763.00
- PMCB N/A
- Revenue This Year
- ZEO N/A
- PMCB N/A
- Revenue Next Year
- ZEO N/A
- PMCB N/A
- P/E Ratio
- ZEO $2.28
- PMCB $2.21
- Revenue Growth
- ZEO N/A
- PMCB N/A
- 52 Week Low
- ZEO $1.05
- PMCB $1.39
- 52 Week High
- ZEO $11.60
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- ZEO 54.35
- PMCB 45.24
- Support Level
- ZEO $1.50
- PMCB $1.60
- Resistance Level
- ZEO $3.05
- PMCB $1.69
- Average True Range (ATR)
- ZEO 0.51
- PMCB 0.11
- MACD
- ZEO -0.03
- PMCB -0.00
- Stochastic Oscillator
- ZEO 43.26
- PMCB 40.00
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.